Accelerate the discovery of new medicines, without exposing sensitive data.

An MSc graduate in Public Health from the London School of Hygiene and Tropical Medicine, he works across public health, migration and digital transformation. After roles in Mozambique, Peru, Kenya and Germany, he is now a Technical Advisor to GIZ’s German–Brazilian Digital Dialogue in Brasília, covering digital health, digital public infrastructure, emerging technologies and information integrity.

Dr. Kai Lindow is an expert in digital technologies with a focus on data and model integration, digital ecosystems, data spaces and AI-driven solutions – always with an eye on business potential. For over a decade, he has been developing systemic approaches to make products and processes more efficient and resource-saving. After studying mechanical engineering in Berlin and Stockholm, he completed his PhD on “Knowledge-based development of sustainable products” at TU Berlin. Following his post-doctoral research at the interface of engineering and computer science, he became head of the Information and Process Control department at Fraunhofer IPK in Berlin, where he now serves as Director of Digital Engineering. He is actively involved in industrial and scientific working groups and a frequent voice on industry and research panels.

At Sirius, he leads the development and application of synchrotron-light techniques for nanomedicine, nanotoxicology, health and environmental research. His strategic work spans the Sibipiruna, Timbó and Hibisco beamlines, integrated into Project Orion and high-containment environments for the safe study of complex biological systems.

He has over ten years of experience in predictive modelling, analytics and data science for pharmaceutical innovation and regulatory toxicology. He is founder and CTO of NanoBusiness and InsilicAll, a Latin American platform combining artificial intelligence and computational methods to accelerate small molecules, protein therapeutics and toxicological safety assessments.

A chemistry professional with 18 years of experience in Research, Development and Innovation. He has led multidisciplinary technical teams, new-product development and global strategic projects. As CEO of InsilicAll, he drives the company’s growth and international expansion by connecting deep chemistry expertise with artificial intelligence.

He has over 20 years of experience in research, development and innovation focused on advanced materials and pharmaceutical solutions. He is founder and Principal Investigator at NanoBusiness and ConvergeLab Venture Builder, de-risking deep-tech opportunities for investors, researcher-entrepreneurs and startups. He also teaches Innovation and Entrepreneurship at UFRJ.

Her pharmaceutical-science work includes experience at the University of São Paulo and the University of Bologna. She took part in the Royal Academy of Engineering’s LIF Global 2026 programme. Her research covers the development, synthesis and characterisation of new solid forms of active pharmaceutical ingredients, crystallography and nanoscience applied to medicine.

A pharmacist, computer scientist and PhD candidate at the University of Tartu, Estonia, where he researches Federated Learning on biased representations. As a researcher at the SESI Innovation Centre for Occupational Health (CIS-SO/Firjan), he works at the intersection of health and AI, developing predictive models and data science solutions to map chronic diseases and build health intelligence. He holds a master’s degree in Applied Informatics from UNIRIO and a specialisation in Hospital Pharmacy from UFRJ.

He received his PhD in Theoretical and Organic Chemistry from the Federal University of Rio de Janeiro in 2001, followed by a postdoctorate with Prof. William Jorgensen at Yale University. He worked at Amgen and then Pfizer, both in the US, as a Senior Principal Scientist. In 2014 he returned to Brazil to lead the Radical Innovation Unit at Aché Laboratórios Farmacêuticos, focused on the discovery and early development of new chemical entities from synthetic and natural sources, and was promoted to Senior Director, Research, Innovation & New Technologies in 2020. He left Aché to start, with Dr. Miller Freitas and Mr. Stephani Saverio, a Brazilian company called Nintx (Next Innovative Therapeutics), which draws on intra- and interspecies biology and derived natural products to generate novel human therapies. He is the author of some 70 publications and patents.

She started as a scientist at USP, then completed a PhD and postdoc at Uppsala University in Sweden. She quickly realised her strength lay not only in generating knowledge but in connecting it: ideas with action, science with decision-making, people with purpose. That belief led her from academia into industry, first pharma and then scientific information and data. For over a decade she has been with the American Chemical Society, where she currently leads Sales and Government Relations for Latin America, doubling and tripling key contracts, negotiating multimillion-dollar agreements and deepening institutional partnerships across Brazil and the region. She advocates for gender equity in STEM and scientific capacity building in the Global South.

Head of Data Analytics & Artificial Intelligence at Peers, he holds a PhD in Sciences from UFRJ and a postdoctoral degree in Computer Simulation from ETH-Zürich, Switzerland. He has been involved in computational research for over 15 years and has published more than 70 international scientific articles, and has been invited to speak in several countries. An entrepreneur, he founded and served as CEO of a data science startup. He has worked on projects with renowned companies in Brazil and abroad, mainly applying data science to R&D, supply chain, customer success and business expansion.

An experienced entrepreneur and startup executive with a strong international network and a solid track record leading fintech and healthtech companies across Europe and the Americas. He is currently the CEO of Open Health Technologies. He studied Business Informatics and IT Management in Berlin and London. Beyond his professional activities, he has a strong interest in biohacking, self-improvement and sports.

President of Equinix in Brazil and one of the leading figures in Latin America’s digital infrastructure sector. With more than 20 years at the company, he has built a career marked by strategic vision, deep technical knowledge and a central role in the country’s digital transformation. In his current position he leads Equinix’s expansion in Brazil, with billions of reais invested in recent years, consolidating the country as a regional hub for interconnection, cloud and AI. He also sits on the board of the Equinix Foundation and the Advisory Board of Escola da Nuvem, reaffirming his commitment to social responsibility and technology’s positive impact on society.

Senior Manager, AI Infrastructure Managed Services Solution Development at Equinix, where for more than 14 years he has built and operated the services underpinning the company’s global Managed Services operation. He currently leads the technical development of the platforms behind Equinix’s IaaS and Private AI portfolio, including NVIDIA DGX SuperPOD and Dell AI Factory solutions, running across AMER, EMEA and APAC. He is NVIDIA Certified in AI Infrastructure and Operations, an alumnus of Wharton’s Leading an AI-Powered Future programme and holds an Executive MBA in Entrepreneurship and New Business Development from FGV. He writes and speaks about the economics of AI infrastructure in production.

Graduated in Biology (2003) with a Master in Biotechnology (2006) from the Federal University of Santa Catarina, and a PhD in Sciences, Biomolecular Physics, from the University of São Paulo (2010). She has developed postdoctoral research at the University of Campinas (2010–2013), the University of California at San Diego (2012) and the University of Nottingham (2015–2016), in the areas of chemistry, natural product biotechnology and molecular pharmacology respectively, with additional training in Project Management from the University of California at San Diego (2022). Her main scientific interests are the discovery of novel bioactive natural products and protein allosteric modulators and their development into new drugs, developing tools for the discovery, characterisation and production of new natural products and customised derivatives for drug discovery projects with academia and industry, applying structural biology methodologies extensively.